| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/16/2001 | WO2001059072A1 Differentiation of bone marrow cells into neuronal cells and uses therefor |
| 08/16/2001 | WO2001059071A2 Methods of preparing and using a viral vector library |
| 08/16/2001 | WO2001059067A2 A group of anti-cancer compounds with specific structure and their production method |
| 08/16/2001 | WO2001058956A2 Antibodies that bind human interleukin-18 and methods of making and using |
| 08/16/2001 | WO2001058954A2 Trade molecules and uses related thereto |
| 08/16/2001 | WO2001058949A2 Heterologous polypeptide of the tnf family |
| 08/16/2001 | WO2001058945A1 Dna encoding human vanilloid receptor vr3 |
| 08/16/2001 | WO2001058937A2 Interferon-alpha induced genes |
| 08/16/2001 | WO2001058936A2 Constructs for delivery of therapeutic agents to neuronal cells |
| 08/16/2001 | WO2001058935A2 FACTOR VII OR VIIa-LIKE MOLECULES |
| 08/16/2001 | WO2001058934A2 Kahalalide f and related compounds |
| 08/16/2001 | WO2001058927A1 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 08/16/2001 | WO2001058922A2 Method and compositions for treating hepatocellular cancer |
| 08/16/2001 | WO2001058921A2 Methods and compositions for generating angiostatin |
| 08/16/2001 | WO2001058916A2 Antibodies to ccr5 |
| 08/16/2001 | WO2001058915A2 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/16/2001 | WO2001058910A2 Lipid-based drug delivery systems |
| 08/16/2001 | WO2001058907A1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058906A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058904A1 Apoptosis-inducing compounds |
| 08/16/2001 | WO2001058902A1 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 08/16/2001 | WO2001058899A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| 08/16/2001 | WO2001058897A1 Benzthiazoles as tnf and pde-iv inhibitors |
| 08/16/2001 | WO2001058896A1 Benzoxazole derivatives as tnf and pde iv inhibitors |
| 08/16/2001 | WO2001058893A2 Indol-3-yl derivatives and their use as integrin inhibitors |
| 08/16/2001 | WO2001058889A1 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| 08/16/2001 | WO2001058886A1 Dipeptide nitrile cathepsin k inhibitors |
| 08/16/2001 | WO2001058881A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 08/16/2001 | WO2001058877A1 Interferon ω production potentiators |
| 08/16/2001 | WO2001058855A1 Use of androgen receptor suppressors |
| 08/16/2001 | WO2001058854A1 A topical antiandrogen for hair loss and other hyperandrogenic conditions |
| 08/16/2001 | WO2001058483A2 METHODS FOR THE PREVENTION AND TREATMENT OF INFECTIONS USING ANTI-C3b(i) ANTIBODIES |
| 08/16/2001 | WO2001058479A1 Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| 08/16/2001 | WO2001058477A2 Immunization of an individual against carcinoma and the preliminary stages thereof |
| 08/16/2001 | WO2001058458A1 Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| 08/16/2001 | WO2001058455A1 Method to potentiate the therapeutic efficacy of taxane and derivatives thereof |
| 08/16/2001 | WO2001058445A1 Therapy with cannabinoids in the treatment of cerebral tumor |
| 08/16/2001 | WO2001058444A1 Use of cyp1b1 inhibitors for treating cancer |
| 08/16/2001 | WO2001058434A2 Diagnostic and therapeutic compositions and methods for affecting tumor growth using oxygen mimetic agents |
| 08/16/2001 | WO2001023550A3 Pca3 messenger rna species in benign and malignant prostate tissues |
| 08/16/2001 | WO2001012172B1 Treatment of metastatic disease |
| 08/16/2001 | WO2001011024A3 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 08/16/2001 | WO2001010842A3 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 08/16/2001 | WO2001010381A3 Methods for treating or preventing pain and anxiety |
| 08/16/2001 | WO2001010380A3 Benzanilides as potassium channel openers |
| 08/16/2001 | WO2001009311A9 Methods of inhibiting cancer cells with adnf iii antisense oligonucleotides |
| 08/16/2001 | WO2001009293A3 Mammalian adhesion protease peptides |
| 08/16/2001 | WO2001009115A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE |
| 08/16/2001 | WO2001007628A3 Human synthetases |
| 08/16/2001 | WO2001007595A3 Novel fibroblast growth factor and nucleic acids encoding same |
| 08/16/2001 | WO2001002569A3 Human immune response molecules |
| 08/16/2001 | WO2001002556A3 Agents for the diagnosis, prognosis and treatment of malignant diseases |
| 08/16/2001 | WO2000076551A3 Method for producing an injectable medicament preparation |
| 08/16/2001 | WO2000066106A3 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 08/16/2001 | WO2000063202A8 BENZO[b] THIOPHENE SULFONAMIDE-1, 1-DIOXIDE DERIVATIVES AND THEIR USE AS ANTINEOPLASTIC AGENTS |
| 08/16/2001 | WO2000046367A3 Proteins capable of triggering g2/m transition and of interacting with cdc2- and cyclin b |
| 08/16/2001 | WO2000044782B1 Ewing's tumour antigen, nucleic acid and antibodies |
| 08/16/2001 | WO1999050658A3 Methods and compounds for modulating nuclear receptor activity |
| 08/16/2001 | US20010014746 Preparation of substituted isoserine esters using metal alkoxides and beta-lactams |
| 08/16/2001 | US20010014695 Therapy for degradation diseases; oxidation resistance |
| 08/16/2001 | US20010014690 Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action |
| 08/16/2001 | US20010014689 Nervous system disorders |
| 08/16/2001 | US20010014681 Compounds useful for inhibition of farnesyl protein transferase |
| 08/16/2001 | US20010014679 Animal growth regulator; controlling cell differentiation, gene expression, glucose metabolism, protein metabolism |
| 08/16/2001 | US20010014474 Preparing hybridoma cell line which produces antibody which specifically recognizes and binds to cell surface antigen associated with a neoplastic human cell; diagnosis, therapy |
| 08/16/2001 | US20010014471 Antitumor agents |
| 08/16/2001 | US20010014464 Nucleic acid encoding follistatin-3 |
| 08/16/2001 | US20010014334 Methods and materials for the treatment of prostatic carcinoma |
| 08/16/2001 | US20010014328 A multispecific binding molecule, comprising a first binding determinant which binds an Fc alpha receptor is not blocked by human immunoglobin A and a second binding determinant binds target cancer cell antigen |
| 08/16/2001 | EP1144997A3 Methods and compounds for modulating nuclear receptor activity |
| 08/16/2001 | EP1144627A3 Proteins capable of triggering g2/m transition and of interacting with cdc2- and cyclin b |
| 08/16/2001 | EP1143946A3 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
| 08/16/2001 | EP1123931A1 Tricylic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| 08/16/2001 | EP1123414A1 Antisense modulation of integrin alpha 4 expression |
| 08/16/2001 | EP1123401A1 BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP) |
| 08/16/2001 | EP1123396A2 Minimal promoters and uses thereof |
| 08/16/2001 | EP1123392A1 Prv-1 gene and the use thereof |
| 08/16/2001 | EP1123387A2 Mn gene and protein |
| 08/16/2001 | EP1123385A2 Human proteins involved in endoplasmic reticulum protein degradation |
| 08/16/2001 | EP1123312A2 Human rna binding proteins |
| 08/16/2001 | EP1123309A2 Cyclic tetrapeptides and their use as histone deacetylase inhibitor |
| 08/16/2001 | EP1123301A1 Chelating agents for radioimmunotherapy |
| 08/16/2001 | EP1123296A1 PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
| 08/16/2001 | EP1123295A1 Bicyclic nitrogen heterocycles |
| 08/16/2001 | EP1123294A1 Novel pterin antineoplastic agents |
| 08/16/2001 | EP1123285A1 Substituted benzopyran analogs for the treatment of inflammation |
| 08/16/2001 | EP1123283A1 Thiazole-derivatives |
| 08/16/2001 | EP1123280A1 Serine protease inhibitor |
| 08/16/2001 | EP1123276A1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them |
| 08/16/2001 | EP1123274A1 Substituted phenyl derivatives, their preparation and use |
| 08/16/2001 | EP1123113A1 Ribozymes used as prodrugs |
| 08/16/2001 | EP1123112A1 Ionic molecular conjugates of n-acylated derivatives of poly (2-amino-2-deoxy-d-glucose) and polypeptides |
| 08/16/2001 | EP1123111A1 Modulation of gene expression by combination therapy |
| 08/16/2001 | EP1123109A1 Contulakin-g, analogs thereof and uses therefor |
| 08/16/2001 | EP1123108A1 Isolated peptides which bind to hla-b35 molecules |
| 08/16/2001 | EP1123099A1 Novel indenoisoquinolines as antineoplastic agents |
| 08/16/2001 | EP1123097A1 Pharmaceutical composition containing decursin |
| 08/16/2001 | EP1123091A1 Combination product comprising an e-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use |
| 08/16/2001 | EP1123086A2 Artificial antigen-specific cells and related methods |
| 08/16/2001 | EP1123008A2 Preparation and use of solidified oils |